1 Aug 2022

Save Antibiotics Now

Content provided by our supplier

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
  • 1000 - 4999
Company types
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer

Other Content from Centrient Pharmaceuticals (9)

  • News Centrient Pharmaceuticals announces completion of acquisition of Astral SteriTech

    Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the completion of the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”).

    With the addition of Astral SteriTech’s Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin sterile injectable finished dosage forms to Centrient’s product portfolio, the company can now further meet the needs of customers and reach more patients with its critical life-saving medicine.

  • Technical Data Overview Available MAs

    Available Marketing Authorizations 
  • News Centrient achieves 100% PNEC compliance

    Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics. Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range.
  • Brochure Finished Dosage Forms Portfolio

    Centrient Pharmaceuticals is a business-to-business provider of generics FDFs, not marketing the products ourselves. Therefore, we do not compete with our customers in the end market. All our dossiers are readily available for out-licensing to our partners worldwide. We work primarily with Europe-based FDFs manufacturers. Customers can be confident that the origin, traceability, and quality of our products are impeccable. We offer a dual sourcing strategy and procurement excellence for our third-party-produced APIs.
  • News Our PureActives® partnerships

    With our innovative enzymatic platform, we've been changing the game for sustainable antibiotics and statins production, step by step.
  • Brochure API Product Portflio

    We are a leading business-to-business provider of generic APIs. We help to secure patient safety, by driving Quality to the next level. Our reputation for producing high-quality generic APIs is well-known throughout the industry. Additionally, our business-to-business customers using our enzymatically produced APIs enjoy the freedom to operate, as these technologies are protected by patents.
  • News Centrient Pharmaceuticals to boost statins manufacturing capacity

    Doubling our API capacity to meet the growing demand
  • News Our ESG Report 2021

    Sustainability matters a great deal to everyone at Centrient Pharmaceuticals, it is core to our mission and essential in shaping our authentic and purposeful culture. Our ESG Ambition means that we not only ‘do what we say,’ but also we are eager to share the significant progress we are making and demonstrate our strong industry leadership position by ‘saying what we do.’ We are proud to share our latest ESG Report 2021 summing up our accomplishments as a company.